CSIR-NCL scientists have developed a novel process platform for the manufacturing purification of a biosimilar rHu Ranibizumab
, A novel cloning, expression refolding platform
Integrated continuous multimodal chromatography for purification
, A two-fold increase in productivity over the existing processes
, Biosimilarity has been demonstrated with Lucentis
Accessibility Controls